Recently, a netizen said on the social platform that Pfizer's 13 price pneumococcal polysaccharide conjugate vaccine (trade name: Peier 13) team had all been laid off. After that, Science Park was responsible for the exclusive import, distribution and promotion of the product in Chinese Mainland, while Pfizer continued to be responsible for product development and production.
On November 24th, Red Star Capital Bureau sought confirmation from Pfizer regarding the above news, and as of the time of publication, there has been no response.
According to Interface News, Pfizer did not respond positively to the layoff incident, but it stated that the cooperation between the two parties "is a win-win cooperation relationship and an efficient market entry model, consolidating the core advantages of the two companies and fully leveraging the synergistic effect of both parties."
It is worth mentioning that at the 5th China International Import Expo in November 2022, Pfizer China signed a strategic cooperation agreement with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to as "Keyuan Trading"), and the two sides will carry out comprehensive cooperation on the storage, distribution, and supply chain services of the 13 valent pneumococcal conjugate vaccine nationwide.
And Science Park Trading is a core pharmaceutical import and distribution enterprise of Shanghai Pharmaceutical Group's Shanghai Pharmaceutical Science Park.
According to a report by China Central Radio and Television Network in April 2015, due to the expiration of Pfizer's Pei'er 7 license, its upgraded product Pei'er 13 has not yet been approved for market launch. Pfizer announced that it will suspend its vaccine business in the relevant regions. According to the Huaxia Times, at that time, there were rumors that Pfizer would lay off its vaccine business team of about 200 people. However, later Pfizer announced to the public that it would search for positions in other business departments for the team.
Until November 2016, Pei'er 13 was approved for marketing as a preventive measure for invasive diseases caused by 13 pneumococcal serotypes in infants and young children aged 6 weeks to 15 months.
In addition to the 13 valent pneumococcal polysaccharide conjugate vaccine, not long ago, Pfizer's COVID-19 drug product line also had new changes.
In January of this year, Pfizer stated in its 2022 annual report that the company would lower its 2023 performance guidance. In the business segment of COVID-19, including COVID-19 Vaccine Comirnaty and COVID-19 Oral Drug Paxlovid, the expected revenue will drop by more than 50% compared with the actual revenue in 2022.
In October, Pfizer announced once again that it will accept 7.9 million courses of Paxlovid refunds from the US government by the end of 2023. It also reiterated the downward revision of the revenue forecast of COVID-19's business segment: Paxlovid and Comirnaty's annual revenue in 2023 is expected to be about $12.5 billion, a decrease of $9 billion from the original estimate.
Red Star News reporter Deng Lingyao